Leigh Anne Hylton Gravatt1, Crystal R Leibrand1, Sulay Patel1, MaryPeace McRae2. 1. Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, 23298, USA. 2. Department of Pharmacotherapy and Outcomes Science, School of Pharmacy, VCU School of Pharmacy, 410 North 12th Street, PO Box 980533, Richmond, VA, 23298-0533, USA. mpmcrae@vcu.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this paper is to review therapies with new mechanisms of action for the treatment of HIV that are at least in phase 2 clinical trials. RECENT FINDINGS: There are several new mechanisms of action being represented within clinical development, including histone deacetylase (HDAC) inhibitors, gene therapies, broadly neutralizing anti-HIV antibodies, immune modulation, and drugs with new mechanisms to block HIV entry. The new therapies are being developed for both as add-on therapy to existing combination antiretroviral therapy and as agents to be used during treatment interruption. The current drugs in development have had varying degrees of success in the early trials. Each of these new drugs may potentially fill a void in current antiretroviral therapy (ART) therapies, which will ultimately lead to improved outcomes in HIV-infected individuals.
PURPOSE OF REVIEW: The purpose of this paper is to review therapies with new mechanisms of action for the treatment of HIV that are at least in phase 2 clinical trials. RECENT FINDINGS: There are several new mechanisms of action being represented within clinical development, including histone deacetylase (HDAC) inhibitors, gene therapies, broadly neutralizing anti-HIV antibodies, immune modulation, and drugs with new mechanisms to block HIV entry. The new therapies are being developed for both as add-on therapy to existing combination antiretroviral therapy and as agents to be used during treatment interruption. The current drugs in development have had varying degrees of success in the early trials. Each of these new drugs may potentially fill a void in current antiretroviral therapy (ART) therapies, which will ultimately lead to improved outcomes in HIV-infected individuals.
Authors: David M Asmuth; Robert L Murphy; Susan L Rosenkranz; Juan J L Lertora; Shyam Kottilil; Yoninah Cramer; Ellen S Chan; Robert T Schooley; Charles R Rinaldo; Nathan Thielman; Xiao-Dong Li; Sharon M Wahl; Jessica Shore; Jennifer Janik; Richard A Lempicki; Yaa Simpson; Richard B Pollard Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard Journal: Lancet HIV Date: 2014-09-15 Impact factor: 12.767
Authors: J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis Journal: J Virol Date: 2000-08 Impact factor: 5.103
Authors: Loyda Ylisastigui; Jason J Coull; Victor C Rucker; Christian Melander; Ronald J Bosch; Scott J Brodie; Lawrence Corey; Donald L Sodora; Peter B Dervan; David M Margolis Journal: J Infect Dis Date: 2004-09-15 Impact factor: 5.226
Authors: Rebecca M Lynch; Eli Boritz; Emily E Coates; Adam DeZure; Patrick Madden; Pamela Costner; Mary E Enama; Sarah Plummer; Lasonji Holman; Cynthia S Hendel; Ingelise Gordon; Joseph Casazza; Michelle Conan-Cibotti; Stephen A Migueles; Randall Tressler; Robert T Bailer; Adrian McDermott; Sandeep Narpala; Sijy O'Dell; Gideon Wolf; Jeffrey D Lifson; Brandie A Freemire; Robert J Gorelick; Janardan P Pandey; Sarumathi Mohan; Nicolas Chomont; Remi Fromentin; Tae-Wook Chun; Anthony S Fauci; Richard M Schwartz; Richard A Koup; Daniel C Douek; Zonghui Hu; Edmund Capparelli; Barney S Graham; John R Mascola; Julie E Ledgerwood Journal: Sci Transl Med Date: 2015-12-23 Impact factor: 17.956
Authors: Ole S Søgaard; Mette E Graversen; Steffen Leth; Rikke Olesen; Christel R Brinkmann; Sara K Nissen; Anne Sofie Kjaer; Mariane H Schleimann; Paul W Denton; William J Hey-Cunningham; Kersten K Koelsch; Giuseppe Pantaleo; Kim Krogsgaard; Maja Sommerfelt; Remi Fromentin; Nicolas Chomont; Thomas A Rasmussen; Lars Østergaard; Martin Tolstrup Journal: PLoS Pathog Date: 2015-09-17 Impact factor: 6.823
Authors: Julian H Elliott; Fiona Wightman; Ajantha Solomon; Khader Ghneim; Jeffrey Ahlers; Mark J Cameron; Miranda Z Smith; Tim Spelman; James McMahon; Pushparaj Velayudham; Gregor Brown; Janine Roney; Jo Watson; Miles H Prince; Jennifer F Hoy; Nicolas Chomont; Rémi Fromentin; Francesco A Procopio; Joumana Zeidan; Sarah Palmer; Lina Odevall; Ricky W Johnstone; Ben P Martin; Elizabeth Sinclair; Steven G Deeks; Daria J Hazuda; Paul U Cameron; Rafick-Pierre Sékaly; Sharon R Lewin Journal: PLoS Pathog Date: 2014-11-13 Impact factor: 6.823
Authors: N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis Journal: Nature Date: 2012-07-25 Impact factor: 49.962
Authors: Charles Gotuaco Ang; Erik Carter; Ann Haftl; Shiyu Zhang; Adel A Rashad; Michele Kutzler; Cameron F Abrams; Irwin M Chaiken Journal: Microorganisms Date: 2021-06-12
Authors: Luis M Bedoya; Manuela Beltrán; Javier García-Pérez; Patricia Obregón-Calderón; Oliver Callies; Ignacio A Jímenez; Isabel L Bazzocchi; José Alcamí Journal: Front Pharmacol Date: 2018-04-18 Impact factor: 5.810